Transplantation Proceedings
Volume 40, Issue 4 , Pages 909-914 , May 2008

Relationship of Hepatitis B or C Virus Prevalences, Risk Factors, and Outcomes in Renal Transplant Recipients: Analysis of German Data

  • V. Kliem

      Affiliations

    • Department of Internal Medicine/Nephrology, Nephrological Center, Hann. Muenden, Germany
    • German
    • International MOST Study Groups.
    • Corresponding Author InformationAddress reprint requests to Volker Kliem, Nephrological Center Niedersachsen, Vogelsang 105, 34346 Hann. Muenden, Germany.
    • ,
  • M. Burg

      Affiliations

    • Department of Internal Medicine/Nephrology, Nephrological Center, Hann. Muenden, Germany
    • ,
  • H. Haller

      Affiliations

    • German
    • ,
  • B. Suwelack

      Affiliations

    • German
    • ,
  • D. Abendroth

      Affiliations

    • German
    • ,
  • L. Fritsche

      Affiliations

    • German
    • ,
  • P. Fornara

      Affiliations

    • German
    • ,
  • F. Pietruck

      Affiliations

    • German
    • ,
  • U. Frei

      Affiliations

    • German
    • ,
  • J. Donauer

      Affiliations

    • German
    • ,
  • A.E. Lison

      Affiliations

    • German
    • ,
  • U. Michel

      Affiliations

    • Novartis Pharma, Germany

References 

  1. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol. 2000;11:1343
  2. Green M, Avery RK, Preiksaitis J. Viral hepatitis guidelines in hemodialysis and transplantation. Am J Transplant. 2004;4(suppl 10):72
  3. Pedroso S, Martins L, Fonseca I, et al. Impact of hepatitis C virus on renal transplantation: association with poor survival. Transplant Proc. 2006;38:1890
  4. Kliem V, Ringe B, Holhorst K, et al. Kidney transplantation in hepatitis B surface antigen carriers. Clin Invest. 1994;72:1000
  5. Kliem V, van den Hoff U, Brunkhorst R, et al. The long-term course of hepatitis C after kidney transplantation. Transplantation. 1996;62:1417
  6. Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant. 2005;5:1701
  7. Chan TM, Lok ASF, Cheng IKP. Hepatitis C in renal transplant recipients. Transplantation. 1991;52:810
  8. Breitenfeldt MK, Rasenack J, Berthold H, et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transpl. 2002;16:130
  9. Lin H-H, Huang C-C, Huang J-Y, et al. Impact of HCV infection on first cadaveric renal transplantation, a single center experience. Clin Transpl. 2004;18:261
  10. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, et al. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant. 2004;19(suppl 3):iii72
  11. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation. 2004;78:745
  12. Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis C virus infection in adult renal graft recipients. Transplant Proc. 2005;37:940
  13. Narula AS, Hooda A, Anand AC, et al. Impact of hepatitis C virus infection in renal transplant recipients. Indian J Gastroenterol. 2005;24:151
  14. Unal E, Turkmen F, Sevinc C, et al. Outcome of renal allograft in Turkish patients with pretransplantation hepatitis C virus infection. Transplant Proc. 2006;38:3448
  15. Mitwalli AH, Alam A, Al-Wakeel J, et al. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients. Nephron Clin Pract. 2006;102:c72
  16. Behzad-Behbahani A, Mojiri A, Tabei SZ, et al. Outcome of hepatitis B and C virus infection on graft function after renal transplantation. Transplant Proc. 2005;37:3045
  17. Chan TM, Chapman J, Lee CJ, et al. A survey on the prevalence and management of hepatitis B after renal transplantation in Asian-Pacific countries. Transplant Proc. 2004;36:2126
  18. Fabrizi F, Martin P, Dixit V, et al. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5:2913
  19. Salvadori M, Rosati A, Bock A, et al. One-year posttransplant renal function is a strong predictor of long-term kidney function: results from the Neoral-MOST observational study. Transplant Proc. 2003;35:2863
  20. Salvadori M, Rosati A, Bertoni E, et al. Low 1-year cyclosporine microemulsion doses are associated with better 5-year renal graft function: an insight from MOST, a multinational observational study. Transplant Proc. 2006;38:1010
  21. Kliem V, Fritsche L, Haller H, et al. Cyclosporine-based immunosuppressive strategies for kidney recipients: interim analysis of German data from the multinational observational study (MOST). Transplant Proc. 2005;37:1597
  22. Dienstag JL. Non-A, non-B hepatitis: I (Recognition, epidemiology and clinical features). Gastroenterology. 1983;85:439
  23. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989;321:1494
  24. Estebàn JI, Gonzáles A, Hernández JM, et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med. 1990;23:1107
  25. Correa JR, Rocha F, Peres AA, et al. Long-term impact of hepatitis B and C virus infection in kidney transplant recipient's survival. Transplant Proc. 2003;35:1076
  26. Einollahi B, Hajarizadeh B, Bakhtiari S, et al. Pretransplant hepatitis C virus infection and its effect on the post-transplant course of living renal allograft recipients. J Gastroenterol Hepatol. 2003;18:836
  27. Kliem V, Michel U, Burg M, et al: Geographical prevalences, risk factors and impacts of hepatitis B and C after renal transplantation: subgroup analysis within the Multinational Observational Study in Transplantation (MOST). Transplant Proc (in press)
  28. Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation. 2001;72:241
  29. Huang CC, Lai MK, Fong MT. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation. 1990;49:540
  30. Rao KV, Kasiske BL, Anderson WR. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation. 1991;51:391
  31. Roth D, Zucker K, Cirocco R, et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int. 1994;45:238
  32. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257
  33. Sabet S, Hakemi M, Nadjafi I, et al. Impact of hepatitis C virus infection on short-term outcome in renal transplantation: a single-center study. Transplant Proc. 2003;35:2699
  34. Manga Sahin G, Sahin S, Kantarci G, et al. Impact of hepatitis C virus infection on patient and graft survival in kidney transplantation. Transplant Proc. 2006;38:499
  35. Mahmoud IM, Elhabashi AF, Elsawy E, et al. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis. 2004;43:131
  36. Glicklich D, Thung SW, Kapoian T, et al. Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant patients. Am J Gastroenterol. 1999;94:159
  37. Matos CAL, Perez RM, Lemos LB, et al. Factors associated with the intensity of liver fibrosis in renal transplant patients with hepatitis B virus infection. Eur J Gastroenterol Hepatol. 2007;19:653
  38. Goffin E, Pirson Y, Cornu C, et al. Outcome of HCV infection after renal transplantation. Kidney Int. 1994;45:551
  39. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation. 1998;66:471
  40. Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun. 2004;313:42
  41. Fabrizi F, Bromberg J, Elli A, et al. Hepatitis C virus and calcineurin inhibition after renal transplantation. Aliment Pharmacol Ther. 2005;22:657
  42. Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev Med Virol. 2007;17:245

 This study was sponsored by Novartis Pharma AG, Basel, Switzerland.

PII: S0041-1345(08)00235-2

doi: 10.1016/j.transproceed.2008.03.031

Transplantation Proceedings
Volume 40, Issue 4 , Pages 909-914 , May 2008

Article Tools

* Image Usage & Resolution